Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants.

Microbiology spectrum - 2 Jun 2026

Ma Yao, Ye Chengjin, Piepenbrink Michael S, Mahmoud Sara H, Cupic Anastasija, Castro Esteban, Jackson Nathaniel, Bayoumi Mahmoud, Padron Alvaro S, García-Sastre Adolfo, Ippolito Gregory C, Walter Mark R, Kobie James J, Martinez-Sobrido Luis

Abstract excerpt

Neutralizing antibodies (NAbs) targeting the spike (S) glycoprotein remain a crucial therapeutic strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, emerging viral variants have escaped all Food and Drug Administration (FDA)-approved NAb treatments, underscoring the urgent need for effective therapeutic alternatives. Using a nanoluciferase (Nluc)-expressing attenuated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to COVID-19

Share to Drug Resistance, Viral

Share to Protein Domains

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 42084370
DOI: 10.1128/spectrum.00006-26
PMCID: PMC13228023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants.PMID 42084370Read ↗

A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutantsSemantic proximity Read ↗

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralizationSemantic proximity Read ↗

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.Semantic proximity Read ↗

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.Semantic proximity Read ↗

Landscape Analysis of Escape Variants Identifies SARS-CoV-2 Spike Mutations that Attenuate Monoclonal and Serum Antibody NeutralizationSemantic proximity Read ↗

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escapeSemantic proximity Read ↗

Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of ConcernSemantic proximity Read ↗

REGEN-COV protects against viral escape in preclinical and human studiesSemantic proximity Read ↗

Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix.Semantic proximity Read ↗

SARS-CoV-2 spike S2-specific neutralizing antibodiesSemantic proximity Read ↗

A bivalent spike-targeting nanobody with anti-sarbecovirus activitySemantic proximity Read ↗

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibodySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.